Skip to content
OPINION (2025/2156(DEC))

On discharge in respect of the implementation of the budget of the EU agencies for the financial year 2024

SANT-AD-779459

Committee on Public Health · Rapporteur: Kateřina Konečná

Official HTML ↗ PDF DOCX
✦ In shortFull textProcedure & committee votes
✦ In short · AI summary of this text, generated 4 Sept 2026

Written by a language model from the full text only; every figure comes from the text. The paragraph links open the paragraph a statement rests on — check the text itself before relying on it.

The Committee on Public Health gives its opinion on granting discharge for the 2024 budgets of the European Centre for Disease Prevention and Control (ECDC) and the European Medicines Agency (EMA). It recommends granting discharge to their Executive Directors. For ECDC, it notes high budget execution and output completion, but flags procurement issues, high carry-overs, and calls for improvements in communication, gender balance, and efficiency. For EMA, it notes budget increases, fee funding, and medicine approvals, but raises concerns about London premises, external data reliance, litigation, and calls for transparency and conflict-of-interest measures.

Committee position. The Committee on Public Health recommends granting discharge to the Executive Directors of ECDC and EMA for the 2024 financial year.

Key points

  1. Welcomes cooperation between Parliament, ECDC and EMA, and considers regular visits key for scrutiny.
  2. Notes ECA confirmed legality and regularity of agencies' 2024 accounts.
  3. For ECDC: notes budget of EUR 93.9 million, high implementation, but high carry-overs; calls for addressing structural planning.
  4. For ECDC: notes 99% of SPD outputs completed or ongoing; calls for including health equity and One Health indicators in future SPDs.
  5. For ECDC: concerned about procurement without prior financing decisions; calls for strengthened checks and training.
  6. For ECDC: notes PHE plan activation for mpox, communication activities, and calls for co-designing strategies with civil society.
  7. For ECDC: calls for tools to monitor AMR, integrate One Health, and enhance collaboration with agricultural and veterinary sectors.
  8. For ECDC: stresses gender balance; regrets senior management is 67% men; calls for equality strategy.
  9. For EMA: notes budget of EUR 478,482,000, surplus, and concerns about London premises; calls on Commission for long-term resolution.
  10. For EMA: notes 89.78% of revenue from fees; calls for transparency.
  11. For EMA: notes 114 new human medicines recommended; calls for strengthening EU clinical evidence capacity.
  12. For EMA: calls for transparency, conflict-of-interest rules, and efficiency improvements.

Who is affected

  • ECDC and EMA: subject to discharge and recommendations for operational improvements.
  • European Commission: called on to resolve EMA's London premises issue.
  • Pharmaceutical industry: pays fees to EMA, which are a major revenue source.

Figures and deadlines

  • ECDC core budget for 2024: EUR 93.9 million, up 4.2% from 2023.
  • ECDC implementation rate: 99.1% commitments, 74.7% paid.
  • ECDC carry-overs from 2023: EUR 22.8 million, 95.8% utilised.
  • EMA total budget 2024: EUR 478,482,000, up 6.8%.
  • EMA surplus 2024: EUR 4,594,984.37 (0.9% of approved budget).
  • EMA fee revenue: 89.78% of C1 revenue in 2024.
  • EMA recommended 114 new human medicines in 2024, up 48%.